APO866 is a new anti-tumor compound inhibiting nicotinamide phosphoribosyltransferase (NAMPT). APO866 has an anti-tumor effect in several pre-clinical tumor models and is currently in several clinical phase II studies. 3'-deoxy-3'-[18F]fluorothymidine ([18F]FLT) is a tracer used to assess cell proliferation in vivo. The aim of this study was non-invasively to study effect of APO866 treatment on [18F]FLT and 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) uptake.
P L O S One, 2013, Vol 8, Issue 1, p. 1-8
Acrylamides; Animals; Antineoplastic Agents; Biological Transport; Cell Proliferation; Clinical Trials, Phase II as Topic; Dideoxynucleosides; Drug Monitoring; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Gene Expression; Humans; Ki-67 Antigen; Mice; Mice, Nude; Nicotinamide Phosphoribosyltransferase; Ovarian Neoplasms; Piperidines; Positron-Emission Tomography; Radiopharmaceuticals; Tumor Burden; Xenograft Model Antitumor Assays; Journal Article; Research Support, Non-U.S. Gov't